Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Assets (2024 - 2025)

Historic Current Assets for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $58.3 million.

  • Prelude Therapeutics' Current Assets fell 6270.15% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year decrease of 6270.15%. This contributed to the annual value of $135.9 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' Current Assets stood at $58.3 million, which was down 6270.15% from $76.9 million recorded in Q2 2025.
  • Prelude Therapeutics' Current Assets' 5-year high stood at $205.4 million during Q1 2024, with a 5-year trough of $58.3 million in Q3 2025.